Patrick M Moriarty
Overview
Explore the profile of Patrick M Moriarty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
111
Citations
3365
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gianos E, Duell P, Toth P, Moriarty P, Thompson G, Brinton E, et al.
Arterioscler Thromb Vasc Biol
. 2024 Oct;
44(12):e304-e321.
PMID: 39370995
Despite the availability of multiple classes of lipoprotein-lowering medications, some high-risk patients have persistent hypercholesterolemia and may require nonpharmacologic therapy. Lipoprotein apheresis (LA) is a valuable but underused adjunctive therapeutic...
2.
Zahger D, Schwartz G, Du W, Szarek M, Bhatt D, Bittner V, et al.
J Am Coll Cardiol
. 2024 Sep;
84(11):994-1006.
PMID: 39232634
Background: It is unknown whether clinical benefit of proprotein convertase subtilisin/kexin type 9 inhibitors is associated with baseline or on-treatment triglyceride concentrations. Objectives: This study sought to examine relations between...
3.
Safarova M, Moriarty P, Kullo I, Ballantyne C, Gianos E
J Am Coll Cardiol
. 2024 Jul;
84(2):163-164.
PMID: 38960509
No abstract available.
4.
Wiegman A, Greber-Platzer S, Ali S, Reijman M, Brinton E, Charng M, et al.
Circulation
. 2023 Oct;
149(5):343-353.
PMID: 37860863
Background: Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by severely elevated low-density lipoprotein cholesterol (LDL-C) levels due to profoundly defective LDL receptor (LDLR) function. Given that severely...
5.
Safarova M, Moriarty P
Curr Atheroscler Rep
. 2023 Jun;
25(7):391-404.
PMID: 37273067
Purpose Of Review: Familial hypercholesterolemia (FH) and hyperlipoproteinemia(a) are relatively common disorders, posing a significant health burden due to increased risk of atherosclerotic cardiovascular disease (ASCVD). Development of electronic health...
6.
Kronenberg F, Mora S, Stroes E, Ference B, Arsenault B, Berglund L, et al.
Atherosclerosis
. 2023 May;
374:107-120.
PMID: 37188555
In 2022, the European Atherosclerosis Society (EAS) published a new consensus statement on lipoprotein(a) [Lp(a)], summarizing current knowledge about its causal association with atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis....
7.
Cuchel M, Lee P, Hudgins L, Duell P, Ahmad Z, Baum S, et al.
J Am Heart Assoc
. 2023 Apr;
12(9):e029175.
PMID: 37119068
Background Homozygous familial hypercholesterolemia (HoFH) is a rare, treatment-resistant disorder characterized by early-onset atherosclerotic and aortic valvular cardiovascular disease if left untreated. Contemporary information on HoFH in the United States...
8.
Rosenson R, Gaudet D, Ballantyne C, Baum S, Bergeron J, Kershaw E, et al.
Nat Med
. 2023 Mar;
29(3):729-737.
PMID: 36879129
Severe hypertriglyceridemia (sHTG) is an established risk factor for acute pancreatitis. Current therapeutic approaches for sHTG are often insufficient to reduce triglycerides and prevent acute pancreatitis. This phase 2 trial...
9.
Nissen S, Lincoff A, Brennan D, Ray K, Mason D, Kastelein J, et al.
N Engl J Med
. 2023 Mar;
388(15):1353-1364.
PMID: 36876740
Background: Bempedoic acid, an ATP citrate lyase inhibitor, reduces low-density lipoprotein (LDL) cholesterol levels and is associated with a low incidence of muscle-related adverse events; its effects on cardiovascular outcomes...
10.
Deshotels M, Hadley T, Roth M, Agha A, Pulipati V, Nugent A, et al.
Arterioscler Thromb Vasc Biol
. 2022 Nov;
42(12):1461-1467.
PMID: 36325899
Background: Severe hypertriglyceridemia is often caused by variants in genes of triglyceride metabolism. These variants include rare, heterozygous pathogenic variants (PVs), or multiple common, small-effect single nucleotide polymorphisms that can...